News
19h
MedPage Today on MSNShould AMA 'Support' a Registry to Track Side Effects of GLP-1 Drugs?CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...
UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...
A new analysis shows no clear link between paternal valproate use and harm in offspring, raising questions about the EMA ...
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
OneSource Specialty Pharma partners with Swedish biotech company Xbrane, on its biosimilar portfolio
OneSource Specialty Pharma partners with Xbrane Biopharma for biosimilar manufacturing, aiming to strengthen global supply ...
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...
Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results